Drug
Sunvozertinib clinical trials
Also written DZD9008.
Keep track of what changes. Save the sunvozertinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 6
Dizal Pharmaceuticals (11) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Peking Union Medical College Hospital (1) · Sichuan University (1) · Sun Yat-sen University (1) · Fudan University (1) · Dizal (Jiangsu) Pharmaceutical Co., Ltd. (1) · Tang-Du Hospital (1)
Often tested with
Tested in the same studies.
Golidocitinib (1) · Carbamazepine (1) · EGFR Mutant-specific Inhibitor DZD6008 (1) · Antineoplastic Agents (1) · Crizotinib (1) · Pralsetinib (1) · Larotrectinib (1) · Savolitinib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses sunvozertinib is read from its arms, and is right about nine times in ten.
Testing it · 18
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)RecruitingPhase 1/2Dizal PharmaceuticalsNCT07079475Written as Sunvozertinib
- Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)RecruitingNot applicablePeking Union Medical College HospitalNCT05559645Written as DZD9008
- Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/IIRecruitingPhase 1/2Sichuan UniversityNCT06195189Written as Sunvozertinib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Sunvozertinib
- Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon MutationsRecruitingPhase 2Fudan UniversityNCT07117890Written as sunvozertinib 300mg
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingPhase 3Dizal (Jiangsu) Pharmaceutical Co., Ltd.NCT07182682Written as sunvozertinib
- Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCRecruitingPhase 2Tang-Du HospitalNCT06864624Written as Sunvozertinib
- DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)RecruitingPhase 2Dizal PharmaceuticalsNCT06276283Written as DZD9008 plus Bevacizumab
- A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)CompletedPhase 2Dizal PharmaceuticalsNCT06295432Written as DZD9008+AZD4205
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingPhase 3Dizal PharmaceuticalsNCT05668988Written as sunvozertinib
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingPhase 1/2Dizal PharmaceuticalsNCT03974022Written as Sunvozertinib
- Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.Active, not recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07274761Written as Sunvozertinib
- Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)WithdrawnPhase 1/2Dizal PharmaceuticalsNCT04148742Written as DZD9008
- Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruitingPhase 2Dizal PharmaceuticalsNCT05712902Written as Sunvozertinib
- DZD9008 PK Study in Hepatic Impairment SubjectsCompletedPhase 1Dizal PharmaceuticalsNCT06084104Written as DZD9008
- Drug-drug Interactions Between DZD9008 and Itraconazole/CarbamazepineCompletedPhase 1Dizal PharmaceuticalsNCT05418582Written as DZD9008 and carbamazepine
- Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult ParticipantsCompletedPhase 1Dizal PharmaceuticalsNCT04909242Written as DZD9008
- Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male SubjectsCompletedPhase 1Dizal PharmaceuticalsNCT05159895Written as [14C]-DZD9008
Given in every arm · 1 — sunvozertinib is usual care beside what is tested
Codes
What other systems call sunvozertinib · ClinicalTrials.gg INT002120
- MeSH (NLM) C000731668sunvozertinibOne source NLM
- UNII (FDA) L1Q2K5JYO8SUNVOZERTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q130051139sunvozertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C167205SunvozertinibOne source FDA
- DrugBank DB18925One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731668 | sunvozertinib | One source NLM |
| UNII (FDA) | L1Q2K5JYO8 | SUNVOZERTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q130051139 | sunvozertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C167205 | Sunvozertinib | One source FDA |
| DrugBank | DB18925 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.